Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has received certification from the German authorities for its 3,600 square metres medical cannabis growing facility.
On Wednesday, the Edmonton-based company announced it has received EU-GMP certification for its medical production facility in Germany by the German Federal Institute for Drugs and Medical Devices (BfArM).
The facility is located in Leuna, Saxony-Anhalt, Germany and supplies high-quality cannabis flower and extracts for medical use by patients across existing markets that currently serves around 100,000 Germans.
In 2019, Aurora was awarded a contract by the German Federal Institute for Drugs and Medical Devices for the annual production of 1,000 kilograms of dried flower over a period of four years.
The first shipment is expected via the state’s cannabis agency later this month.
Read more: Aurora Cannabis to buy Thrive for $38M
“With the EU-GMP certification of our first German site, we once again demonstrate Aurora’s excellence and leadership in establishing the necessary infrastructure to compete in the global cannabis market,” Aurora CEO Miguel Martin said in a statement.
“As a leading provider of medical cannabis in Germany and several other European markets, we are eager to accelerate patient access to high-quality, reliable cannabis produced in accordance with the most stringent criteria,” he said.
Marifirst added that the shipment from the world-class Leuna facility will expand the patient base which is a significant step in the company’s ongoing commitment to international market growth.
Aurora recently shut down its operation at its Aurora Sky facility in Edmonton, Alberta. It owns brands including Aurora Drift, San Rafael ’71, Daily Special, and Whistler.
Company stock went down by 6.06 per cent on Wednesday to $3.72 on the Toronto Securities Exchange.